Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Rome, Italy – 28 August, 2016: A therapy that uses bone-marrow stem cells to promote heart repair did not significantly improve the primary outcome over a sham procedure among patients with congestive heart failure. However, it revealed critical new insights, according to investigators of the CHART-1 trial.
Although findings of CHART-1 (Congestive Heart Failure Cardiopoietic Regenerative Therapy) were neutral in the overall patient population, an exploratory analysis identified a sub-group of patients who may benefit from cardiopoietic cell therapy, according to the principal co-investigator of the study Jozef Bartunek, MD, PhD, from OLV Hospital Aalst, Belgium.
“Within a well-defined patient population, based on baseline heart failure severity, this therapy showed benefit,” said Prof Bartunek, who presented the findings at ESC Congress 2016. “Lessons learned from CHART-1 will now provide the foundation for the design of the ensuing CHART-2 trial which will target these patients.”
Cardiopoietic cell therapy involves the isolation of mesenchymal stem cells from a patient’s own bone marrow. Exposing these cells to a “cardiogenic cocktail” turns them into cardiopoietic cells which are then injected into damaged heart tissue.
The CHART-1 study randomized patients with symptomatic ischemic heart failure from 39 hospital centres in Europe and Israel.
Patients received either a sham procedure (n=151) or cardiopoietic cells (n=120).
At 39 weeks there was no significant difference between groups for the primary efficacy endpoint, which was a composite of all-cause mortality, worsening heart failure events, Minnesota Living with Heart Failure Questionnaire total score, 6-minute walk distance, left ventricular end-systolic volume and ejection fraction.
However, a subgroup analysis of patients with severe heart enlargement at baseline (left ventricular end-diastolic volumes between 200 and 370 mL) suggested a positive effect of the cell treatment over sham.
“Outcomes for all components of the composite endpoint, including mortality and worsening heart failure, were “directionally consistent” said Prof Bartunek, adding that “the effect was also related to clinically meaningful improved quality of life, greater 6-minute walk distance, and reduced left ventricular end-systolic volume for cell treatment versus sham.”
In addition, “we observed a modifying effect of treatment intensity with suggestion of a greater benefit at lower number of injections,” he added. “Overall safety was demonstrated across the study cohort, with no difference in adverse clinical outcomes observed between the groups.”
Ongoing analyses will evaluate 12-month clinical outcomes, said Prof Bartunek. “Insights from the CHART-1 trial have implications for targeting the patient population that should be considered for cardiopoietic cell therapy in future clinical trials or for broader clinical considerations. More generally, indices of heart failure severity and optimized therapeutic intensity should be considered.”
Sources of funding: The trial was funded by Celyad, SA (Mont-Saint-Guibert, Belgium).
Disclosures: Jozef Bartunek is a member of CVBA Cardiovasculair Onderzoek an institution which co-founded Cardio3Biosciences (currently Celyad). All consultancy/speakers fees and research contracts are directed to Cardiovasculair Onderzoek and Cardiac Research Institute, Aalst, BE.
ESC Press Office For background information, please contact the ESC Press Office.
For press enquiries, please contact, the Media & Press Coordinator, Jacques Olivier Costa: +393427028575
For independent comment on site, please contact the ESC Spokesperson coordinator, Celine Colas: +393402405148
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
About the European Society of Cardiology The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
About ESC Congress 2016
ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The scientific programme is here. More information is available from the ESC Press Office at firstname.lastname@example.org
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2016. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved